{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:33:56Z","timestamp":1793118836221,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ebiom.2021.103705","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:36:19Z","timestamp":1638275779000},"page":"103705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":203,"special_numbering":"C","title":["Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial"],"prefix":"10.1016","volume":"74","author":[{"given":"Peter","family":"Bergman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"S\u00f6derdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. I. Edvard","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-0394","authenticated-orcid":false,"given":"David","family":"Wullimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vesterbacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustaf","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Blixt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Friman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Wahren-Borgstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nordlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica Cuapio","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Akber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Carin","family":"Norlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Thalme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Bogdanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Muschiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0605-8417","authenticated-orcid":false,"given":"Sophia","family":"Hober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret S\u00e4llberg","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Buggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Gustaf","family":"Ljunggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-4870","authenticated-orcid":false,"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ebiom.2021.103705_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002630","article-title":"COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies","volume":"9","author":"Goldman","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"22","key":"10.1016\/j.ebiom.2021.103705_bib0002","first-page":"11926","article-title":"Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review","volume":"24","author":"Kim","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103705_bib0003","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/s41409-020-0919-0","article-title":"The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy","volume":"55","author":"Ljungman","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103705_bib0004","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.ebiom.2021.103705_bib0005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103705_bib0006","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1111\/ajt.16726","article-title":"Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2","volume":"21","author":"Firket","year":"2021","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103705_bib0007","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"23","key":"10.1016\/j.ebiom.2021.103705_bib0008","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103705_bib0009","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103705_bib0010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jhep.2021.04.020","article-title":"Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients","volume":"75","author":"Rabinowich","year":"2021","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.ebiom.2021.103705_bib0011","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.ebiom.2021.103705_bib0012","first-page":"840","volume":"9","author":"Lukaszuk","year":"2021","journal-title":"Usefulness of IVD Kits for the Assessment of SARS-CoV-2 Antibodies to Evaluate the Humoral Response to Vaccination"},{"issue":"19","key":"10.1016\/j.ebiom.2021.103705_bib0013","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 - Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2021.103705_bib0014","unstructured":"2021. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html."},{"issue":"17","key":"10.1016\/j.ebiom.2021.103705_bib0015","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2021.4385","article-title":"Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ebiom.2021.103705_bib0016","doi-asserted-by":"crossref","first-page":"1173.e1","DOI":"10.1016\/j.cmi.2021.04.028","article-title":"Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study","volume":"27","author":"Rozen-Zvi","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103705_bib0017","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2021.103705_bib0018","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021011841","article-title":"COVID-19 in patients with CLL: improved survival outcomes and update on management strategies","author":"Roeker","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ebiom.2021.103705_bib0019","first-page":"00612","article-title":"Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency","volume":"S0091-6749","author":"Lu","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"25","key":"10.1016\/j.ebiom.2021.103705_bib0020","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.1093\/hmg\/ddv437","article-title":"DCLRE1C (ARTEMIS) mutations causing phenotypes ranging from atypical severe combined immunodeficiency to mere antibody deficiency","volume":"24","author":"Volk","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"14","key":"10.1016\/j.ebiom.2021.103705_bib0021","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.2021012769","article-title":"Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy","volume":"138","author":"Dhakal","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ebiom.2021.103705_bib0022","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"10297","key":"10.1016\/j.ebiom.2021.103705_bib0023","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(21)01594-4","article-title":"Antibody response after second BNT162b2 dose in allogeneic HSCT recipients","volume":"398","author":"Redjoul","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103705_bib0024","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/QAD.0000000000002945","article-title":"Safety and antibody response to the first dose of SARS-CoV-2 messenger RNA vaccine in persons with HIV","volume":"35","author":"Ruddy","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2021.103705_bib0025","first-page":"ciab648","article-title":"The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with HIV","volume":"22","author":"Woldemeskel","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103705_bib0026","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/imr.12079","article-title":"HIV-associated chronic immune activation","volume":"254","author":"Paiardini","year":"2013","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103705_bib0027","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40121-017-0166-x","article-title":"Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I","volume":"6","author":"Crum-Cianflone","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"14","key":"10.1016\/j.ebiom.2021.103705_bib0028","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1097\/QAD.0b013e32833c6d5c","article-title":"Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals","volume":"24","author":"Tebas","year":"2010","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103705_bib0029","doi-asserted-by":"crossref","first-page":"938.e1","DOI":"10.1016\/j.jtct.2021.07.008","article-title":"Safety and Tolerability of SARS-CoV-2 Emergency-Use Authorized Vaccines Allogeneic Hematopoietic Stem Cell Transplant Recipients","volume":"27","author":"Ali","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103705_bib0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.vaccine.2013.11.073","article-title":"Comparable humoral response after two doses of adjuvanted influenza A\/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients","volume":"32","author":"Dhedin","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2021.103705_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.12339","article-title":"Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses","author":"Benotmane","year":"2021","journal-title":"JAMA"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421004990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421004990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:34:41Z","timestamp":1764866081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396421004990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"alternative-id":["S2352396421004990"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103705","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.07.21263206","asserted-by":"object"}]},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103705"}}